Kowa, Eli Lilly report results of pre-specified safety analysis of INTREPID trial
Kowa Pharmaceuticals America and Eli Lilly and Company have reported results of the pre-specified safety analysis from the INTREPID trial, a phase IV study designed to evaluate Livalo (pitavastatin) 4mg against pravastatin 40mg in HIV-infected patien… (Source: Drug Development Technology)
Source: Drug Development Technology - June 18, 2013 Category: Pharmaceuticals Source Type: news
Risk of Diabetes With Statins Risk of Diabetes With Statins
While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Two studies address diabetes risks with statins—one good news, one so-so
While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin. (Source: theHeart.org)
Source: theHeart.org - May 23, 2013 Category: Cardiology Source Type: news
Horizon Scanning: Pitavastatin versus pravastatin for LDL cholesterol reduction in HIV infected adults with dyslipidaemia
Source: BioSpace
Area: News
According to a report in BioSpace, results of a comparative superiority study investigating pitavastatin 4mg versus pravastatin 40mg in adult HIV infected patients with dyslipidaemia met its primary endpoint, percent reduction in LDL cholesterol, and reported that, after 12 weeks of therapy, pitavastatin had a significantly greater decrease in LDL cholesterol compared with pravastatin (pitavastatin 31% vs. pravastatin 21% reduction, p<0.001).
The overall incidence of treatment emergent adverse events was 61.1% for pitavastatin and 62.7% for pravastatin.
Pravastatin is...
Source: NeLM - Cardiovascular Medicine - March 8, 2013 Category: Cardiology Source Type: news
